Clinical trials: Crohns Disease
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting.
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- LUNAR (NCT07532213)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Janssen-Cilag A.G., Switzerland
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 306 (NCT03566823)
- Testing
- Ontamalimab
- Where
- 145 sites in United States, Argentina and 18 more
- Volunteers
- 34 people
- Sponsor
- Shire
Crohn's Disease
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
- Trial name
- CD04 (NCT00739986)
- Testing
- Semapimod
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 152 people
- Sponsor
- Ferring Pharmaceuticals
Intestinal Disease, Inflammatory Bowel Disease
Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease
The purpose of this study is to compare the clinical findings involving the small bowel obtained with the Capso Vision Video Capsule Device to those results obtained with the PillCam SB2.
- Conditions
- Intestinal Disease, Inflammatory Bowel Disease, Crohn Disease, Ulcer
- Trial name
- NCT01787825
- Testing
- PillCam SB2 capsule, CapsoCam SV-1
- Where
- 7 sites in United States, Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Capso Vision, Inc.
Crohn Disease
EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
A Phase 1, 2-part, multicentre study to evaluate the safety and preliminary efficacy of the oral administration of EXL01 in the maintenance of corticosteroid-induced clinical response/remission in participants with mild to…
- Trial name
- MAINTAIN (NCT05542355)
- Testing
- EXL01, SoC corticosteroid - Induction Period, SoC corticosteroid - Tapering
- Where
- 5 sites in Belgium, Poland
- Volunteers
- 8 people
- Sponsor
- Exeliom Biosciences
Crohn Disease
Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease
The investigational product, named Ovasave (Ova-Treg), is a cell-based therapy, consisting of an autologous antigen-specific regulatory type 1 T lymphocyte expanded population administered via the intravenous route as an…
- Trial name
- CATS29 (NCT02327221)
- Testing
- Ovasave
- Where
- 29 sites in Austria, Belgium and 4 more
- Volunteers
- 32 people
- Sponsor
- TxCell
Healthy Subjects, Crohns Disease
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects…
- Trial name
- NCT05452304
- Testing
- AZD7798
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Crohn Disease
VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.
- Trial name
- Harmony-CD (NCT05688852)
- Testing
- VTX958
- Where
- 105 sites in United States, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Ventyx Biosciences, Inc
Crohn Disease, Rectal Fistula
A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease
Natural Language Processing and machine learning are examples of artificial intelligence tools. This study will check if these tools correctly identify people with Crohn's disease with complex perianal fistulas from their medical…
- Trial name
- INTUITION-CPF (NCT04844593)
- Where
- 3 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Takeda
Crohns Disease, Colitis, Ulcerative
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile…
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Trial name
- TRILOGY (NCT06663332)
- Testing
- Guselkumab
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.
- Trial name
- NCT02015793
- Testing
- Adalimumab
- Volunteers
- 30 people
- Sponsor
- AbbVie
Crohn's Disease, Colitis
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD).
- Conditions
- Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease
- Trial name
- NCT00072943
- Testing
- anti-Interferon-gamma monoclonal antibody
- Where
- 19 sites in United States, Canada
- Volunteers
- 175 people
- Sponsor
- Facet Biotech
Crohn Disease
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old in other countries and determine if it is…
- Trial name
- STELARA (NCT02968108)
- Testing
- Ustekinumab
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Fistulizing Crohn's Disease
Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease
The primary objective of this study is to investigate the safety and tolerability of locally administered DLX105 in treating enterocutaneous fistulas in Crohn's Disease patients.
- Trial name
- NCT01624376
- Testing
- DLX105
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Delenex Therapeutics AG
Ulcerative Colitis, Crohn's Disease
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.
- Trial name
- NCT03138655
- Testing
- Vedolizumab
- Where
- 88 sites in United States, Belgium and 9 more
- Volunteers
- 89 people
- Sponsor
- Takeda
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Intestinal Stricture, Crohn Disease
NaviCam Patency Capsule to Verify Gastrointestinal Patency
Participants included in this study will first swallow a patency capsule and then undergo an abdominal X-ray scan within 30 hours after swallowing the capsule to confirm weather the capsule is still in the body.
- Conditions
- Intestinal Stricture, Crohn Disease, NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, Abdominal Pain
- Trial name
- PATENCY (NCT07649720)
- Testing
- NaviCam Patency Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- AnX Robotica Corp.
Crohn's Disease
B0151005 Open-Label Extension Study
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders.
- Trial name
- ANDANTE II (NCT01345318)
- Testing
- PF-04236921
- Where
- 127 sites in United States, Australia and 14 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Ulcerative Colitis, Crohn's Disease
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (CD). This is happening because people are living longer and because more people overall are developing UC or…
- Trial name
- NCT07250815
- Testing
- No intervention
- Where
- United States
- Sponsor
- Takeda
Ulcerative Colitis, Crohn's Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase…
- Trial name
- NCT03650413
- Testing
- UTTR1147A
- Where
- 57 sites in United States, Bulgaria and 12 more
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.